Targeting Thrombophilia in Sickle Cell Disease with Isoquercetin: Results of a Fixed Dose, Single Center, Phase II Randomized Clinical Trial | Literature Database for Quercetin, Rutin, Isorhamnetin, and Their Related Compounds | Alps Pharmaceutical Ind. Co.,Ltd.

Literature Database for Quercetin, Rutin, Isorhamnetin, and Their Related Compounds

Targeting Thrombophilia in Sickle Cell Disease with Isoquercetin: Results of a Fixed Dose, Single Center, Phase II Randomized Clinical Trial

Authors:: Maria A. Lizarralde-Iragorri; Bindu Parachalil Gopalan; Brenda Merriweather; Jennifer Brooks; Mai Hill; Anna Conrey; Ruth Pierre Charles; Eveline Gwaabe; Neal Jeffries; Arun S. Shet

Reference:: Blood; 2022; 140, Supplement 1; 8270–8271

DOI:: 10.1182/blood-2022-166518

See Abstract

Key Words:: Phase II clinical trial; randomization; double blind; placebo controlled; parallel-group; sickle cell disease; isoquercetin; soluble P-selectin; negative data

Back to index